[Lamotrigine in the therapy of resistant epilepsy].

Objective: To evaluate the efficacy of lamotrigine as single agent in patients with refractory epilepsy.

Materials And Methods: Forty-seven adult patients with refractory epilepsy, in the initial phase received carbamazepine (1208 +/- 82.9 mg/day) plus lamotrigine (561.

[Efficacy of vigabatrin associated with carbamazepine in the treatment of epilepsy. Follow up 1993-1996].

Purpose: To verify tolerance and clinical efficacy of vigabatrin (VGB), a new antiepileptic drug, in an add-on therapy with carbamazepine (CBZ).

Patients And Methods: From september 1993 to december 1996, 35 patients with partial complex seizures (CPC) and CPC plus secondary generalization were treated, with VGB plus CBZ, VGB dose was 1.41 +/- 0.

[Lamotrigine: monotherapy in refractory epilepsy].

CBZ (mean 1219 mg, DS +/- 94.6) + LTG (mean 55.8 mg, DS +/- 80) were administered in 31 subjects with refractory partial complex and/or partial secondary generalized seizures.

[Felbamate: a long-term study in subjects with refractory epilepsy].

Unlabelled: 18 patients with refractory complex partial seizures with or without secondary generalization resistant at common AED were studied. They were treated in a open label study with felbamate for a 22 months period. Felbamate monotherapy show a statistical significant improvement in the control of seizures in these patients versus CBZ therapy.

[Lamotrigine: first experience in Italy].

LTG, lamotrigine is a new antiepileptic agent chemically unrelated to any established drugs in use. The safety and the efficacy of LTG (564.5 +/- 74.